tetano
Editor, Senior Moderator
Liver Int
. 2022 Feb 2.
doi: 10.1111/liv.15173. Online ahead of print.
Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection
Taiyu He[SUP] 1 [/SUP], Yingzhi Zhou[SUP] 1 [/SUP], Pan Xu[SUP] 1 [/SUP], Ning Ling[SUP] 1 [/SUP], Min Chen[SUP] 1 [/SUP], Tianquan Huang[SUP] 1 [/SUP], Biqiong Zhang[SUP] 1 [/SUP], Ziqiao Yang[SUP] 1 [/SUP], Ling Ao[SUP] 1 [/SUP], Hu Li[SUP] 1 [/SUP], Zhiwei Chen[SUP] 1 [/SUP], Dazhi Zhang[SUP] 1 [/SUP], Xiaofeng Shi[SUP] 1 [/SUP], Yu Lei[SUP] 1 [/SUP], Zhiyi Wang[SUP] 1 [/SUP], Weiqun Zeng[SUP] 1 [/SUP], Peng Hu[SUP] 1 [/SUP], Yinghua Lan[SUP] 1 [/SUP], Zhi Zhou[SUP] 1 [/SUP], Juan Kang[SUP] 1 [/SUP], Ying Huang[SUP] 1 [/SUP], Tongdong Shi[SUP] 1 [/SUP], Qingbo Pan[SUP] 1 [/SUP], Qian Zhu[SUP] 1 [/SUP], Xiping Ran[SUP] 1 [/SUP], Yingzhi Zhang[SUP] 1 [/SUP], Rui Song[SUP] 1 [/SUP], Dejuan Xiang[SUP] 1 [/SUP], Shuang Xiao[SUP] 1 [/SUP], Gaoli Zhang[SUP] 1 [/SUP], Wei Shen[SUP] 1 [/SUP], Mingli Peng[SUP] 1 [/SUP], Dachuan Cai[SUP] 1 [/SUP], Hong Ren[SUP] 1 [/SUP]
Affiliations
Abstract
Background & aims: The safety and antibody responses of coronavirus disease 2019 (COVID-19) vaccination in patients with chronic hepatitis B (CHB) virus infection is still unclear, and exploration in safety and antibody responses of COVID-19 vaccination in CHB patients is significant in clinical practice.
Methods: 362 adult CHB patients and 87 healthy controls at an interval of at least 21 days after full-course vaccination (21-105 days) were enrolled. Adverse events (AEs) were collected by questionnaire. The antibody profiles at 1, 2 and 3 months were elucidated by determination of anti-spike IgG, anti-receptor binding domain (RBD) IgG, and RBD-angiotensin-converting enzyme 2 blocking antibody. SARS-CoV-2 specific B cells were also analyzed.
Results: All AEs were mild and self-limiting, and the incidence was similar between CHB patients and controls. Seropositivity rates of three antibodies were similar between CHB patients and healthy controls at 1, 2 and 3 months, but CHB patients had lower titers of three antibodies at 1 month. Compared to healthy controls, HBeAg-positive CHB patients had higher titers of three antibodies at 3 month (all p<0.05) and a slower decline in antibody titers. Frequency of RBD-specific B cells was positively correlated with titers of anti-RBD IgG (OR=1.067, p=0.004), while liver cirrhosis, antiviral treatment, levels of HBV DNA, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and total bilirubin (TB) were not correlated with titers of anti-RBD IgG.
Conclusions: Inactivated COVID-19 vaccines were well tolerated, and induced effective antibody response against SARS-CoV-2 in CHB patients.
Keywords: CHB; COVID-19 vaccine; antibody response; cirrhosis; safety.
. 2022 Feb 2.
doi: 10.1111/liv.15173. Online ahead of print.
Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection
Taiyu He[SUP] 1 [/SUP], Yingzhi Zhou[SUP] 1 [/SUP], Pan Xu[SUP] 1 [/SUP], Ning Ling[SUP] 1 [/SUP], Min Chen[SUP] 1 [/SUP], Tianquan Huang[SUP] 1 [/SUP], Biqiong Zhang[SUP] 1 [/SUP], Ziqiao Yang[SUP] 1 [/SUP], Ling Ao[SUP] 1 [/SUP], Hu Li[SUP] 1 [/SUP], Zhiwei Chen[SUP] 1 [/SUP], Dazhi Zhang[SUP] 1 [/SUP], Xiaofeng Shi[SUP] 1 [/SUP], Yu Lei[SUP] 1 [/SUP], Zhiyi Wang[SUP] 1 [/SUP], Weiqun Zeng[SUP] 1 [/SUP], Peng Hu[SUP] 1 [/SUP], Yinghua Lan[SUP] 1 [/SUP], Zhi Zhou[SUP] 1 [/SUP], Juan Kang[SUP] 1 [/SUP], Ying Huang[SUP] 1 [/SUP], Tongdong Shi[SUP] 1 [/SUP], Qingbo Pan[SUP] 1 [/SUP], Qian Zhu[SUP] 1 [/SUP], Xiping Ran[SUP] 1 [/SUP], Yingzhi Zhang[SUP] 1 [/SUP], Rui Song[SUP] 1 [/SUP], Dejuan Xiang[SUP] 1 [/SUP], Shuang Xiao[SUP] 1 [/SUP], Gaoli Zhang[SUP] 1 [/SUP], Wei Shen[SUP] 1 [/SUP], Mingli Peng[SUP] 1 [/SUP], Dachuan Cai[SUP] 1 [/SUP], Hong Ren[SUP] 1 [/SUP]
Affiliations
- PMID: 35107848
- DOI: 10.1111/liv.15173
Abstract
Background & aims: The safety and antibody responses of coronavirus disease 2019 (COVID-19) vaccination in patients with chronic hepatitis B (CHB) virus infection is still unclear, and exploration in safety and antibody responses of COVID-19 vaccination in CHB patients is significant in clinical practice.
Methods: 362 adult CHB patients and 87 healthy controls at an interval of at least 21 days after full-course vaccination (21-105 days) were enrolled. Adverse events (AEs) were collected by questionnaire. The antibody profiles at 1, 2 and 3 months were elucidated by determination of anti-spike IgG, anti-receptor binding domain (RBD) IgG, and RBD-angiotensin-converting enzyme 2 blocking antibody. SARS-CoV-2 specific B cells were also analyzed.
Results: All AEs were mild and self-limiting, and the incidence was similar between CHB patients and controls. Seropositivity rates of three antibodies were similar between CHB patients and healthy controls at 1, 2 and 3 months, but CHB patients had lower titers of three antibodies at 1 month. Compared to healthy controls, HBeAg-positive CHB patients had higher titers of three antibodies at 3 month (all p<0.05) and a slower decline in antibody titers. Frequency of RBD-specific B cells was positively correlated with titers of anti-RBD IgG (OR=1.067, p=0.004), while liver cirrhosis, antiviral treatment, levels of HBV DNA, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and total bilirubin (TB) were not correlated with titers of anti-RBD IgG.
Conclusions: Inactivated COVID-19 vaccines were well tolerated, and induced effective antibody response against SARS-CoV-2 in CHB patients.
Keywords: CHB; COVID-19 vaccine; antibody response; cirrhosis; safety.